Anzeige
Meldung des Tages: NASDAQ, Washington, Psychedelika – und Optimi steht im Zentrum der Explosion

Oncolytics Biotech News

Aktie
WKN:  A2JMW5 ISIN:  CA6823108759 Branche:  Biotechnologie Land:  Kanada
0,9403 $
+0,0854 $
+9,99%
0,7978 € 01.04.26
Depot/Watchlist
Marktkapitalisierung *
62,33 Mio. €
Streubesitz
94,71%
KGV
-3,21
Index-Zuordnung
Nasdaq Composite Index

Oncolytics Biotech News

19.03.26 - PR Newswire
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire
05.03.26 - PR Newswire
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Next-​Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types PR Newswire
03.03.26 - PR Newswire
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion PR Newswire
25.02.26 - PR Newswire
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Immuno-​Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 PR Newswire
24.02.26 - PR Newswire
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge PR Newswire
17.02.26 - PR Newswire
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire
17.02.26 - PR Newswire
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire
05.02.26 - PR Newswire
$207B Market Shift: The Race for Fast Track Approval in Oncology
$207B Market Shift: The Race for Fast Track Approval in Oncology PR Newswire
30.01.26 - PR Newswire
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
$170B Patent Cliff Ignites Biotech Deal Wave: Late-​Stage Platforms Command Premium PR Newswire
30.01.26 - PR Newswire
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire
28.01.26 - PR Newswire
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
Late-​Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment PR Newswire
28.01.26 - PR Newswire
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
Late-​Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment PR Newswire
27.01.26 - PR Newswire
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
Registration-​Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks PR Newswire
14.01.26 - PR Newswire
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff PR Newswire
12.01.26 - PR Newswire
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
Fast-​Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 PR Newswire
07.01.26 - PR Newswire
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
How $594B in Precision Tech is Cracking the Metastatic Cancer Code PR Newswire
31.12.25 - PR Newswire
Smart Oncology: 5 Stocks Chasing the $317B Prize
Smart Oncology: 5 Stocks Chasing the $317B Prize PR Newswire
16.12.25 - PR Newswire
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B PR Newswire
12.12.25 - PR Newswire
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance PR Newswire
28.10.25 - PR Newswire
Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care PR Newswire

Newssuche

Videos

newspaper
20.04.26 -0,34%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »